Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108836 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00108836 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 400 participants.
The verdict
NCT00108836, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
Interventions
- DRUG XBD173
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108836
The ClinicalTrials.gov registry entry for NCT00108836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XBD173 is the first listed.
NCT00108836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108836 about?
NCT00108836 is a clinical study titled "Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder". This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
What is the current status of trial NCT00108836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2005-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00108836?
The interventions under investigation include: XBD173 (DRUG).
Who is sponsoring clinical trial NCT00108836?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.